“…Survivors of HL are at increased risk of multiple non-cancer morbidities (Aleman et al, 2007;Galper et al, 2011;Schellong et al, 2010;Adams et al, 2004;De Bruin et al, 2009b;Bowers et al, 2005;De et al, 2014;Venkatramini et al, 2014;Oguz et al, 2007;Sklar et al, 2000;Krull et al, 2012;De Bruin et al, 2008;Behringer et al, 2013;van der Kaaij et al, 2012;Daniels et al, 2014;Ruffer et al, 2003;Zebrack et al, 2002;Oerlemans et al, 2011). We have described the number of TYA HL survivors who experienced severe late effects necessitating inpatient hospitalisation and interpreted this as a surrogate marker of morbidity.…”